Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

.flex_column.av-s3q6d-55d0739350db1bc03ec0182f4f5653f8{ border-radius:0px 0px 0px 0px; padding:0px 0px 0px 0px; } #top .av-special-heading.av-av_heading-9a352eec7d78182eca218caabf126019{ padding-bottom:10px; } body .av-special-heading.av-av_heading-9a352eec7d78182eca218caabf126019 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-av_heading-9a352eec7d78182eca218caabf126019 .av-subheading{ font-size:16px; } Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746 – NB-4746 is being developed as a neuroprotective therapy for n